{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:02Z","timestamp":1790369942669,"version":"4.1.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Smoldering multiple myeloma (SMM) is an asymptomatic precursor of multiple myeloma characterized by marked heterogeneity in the risk of progression. Current management relies on clinical risk stratification to identify patients who might benefit from early intervention. Models such as the 20\/2\/20 score and its International Myeloma Working Group refinement incorporate tumor burden and cytogenetic abnormalities, whereas emerging approaches integrating dynamic biomarkers, circulating tumor cells, genomic alterations, and immune signatures could further improve the prediction of progression if validated in larger cohorts. Randomized trials suggest that early treatment with lenalidomide-based regimens or anti-CD38 monoclonal antibodies delays progression and possibly improves survival in high-risk SMM, and daratumumab has been approved as an early intervention in high-risk SMM. More intensive immunotherapy-based strategies can achieve high rates of sustained measurable residual disease negativity, which might translate into durable disease control or even a cure. Future management will likely depend on biologically informed, risk-adapted strategies to balance early treatment benefits against overtreatment, together with safety profile and patients\u2019 preferences.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000848","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:00:55Z","timestamp":1790366455000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Smoldering and Early Disease Interception"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1491-5358","authenticated-orcid":false,"given":"Borja","family":"Puertas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Alejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20260925","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260925","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers"},{"key":"R3-20260925","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"R4-20260925","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-20260925","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"key":"R6-20260925","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R7-20260925","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20260925","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"R9-20260925","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"R10-20260925","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"R11-20260925","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"R12-20260925","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","article-title":"Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma","volume":"28","author":"Termini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"R13-20260925","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2025-493","article-title":"Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)","volume":"146","author":"Martin-Sanchez","year":"2025","journal-title":"Blood"},{"key":"R14-20260925","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"key":"R15-20260925","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1002\/hem3.76","article-title":"The evolving pattern of the monoclonal protein improves the IMWG 2\/20\/20 classification for patients with smoldering multiple myeloma","volume":"8","author":"De Daniel","year":"2024","journal-title":"HemaSphere"},{"key":"R16-20260925","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"},{"key":"R17-20260925","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-024-01053-3","article-title":"The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression","volume":"14","author":"Medina-Herrera","year":"2024","journal-title":"Blood Cancer J"},{"key":"R18-20260925","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.22.01916","article-title":"Definition and clinical significance of the monoclonal gammopathy of undetermined significance\u2013like phenotype in patients with monoclonal gammopathies","volume":"41","author":"Burgos","year":"2023","journal-title":"JCO"},{"key":"R19-20260925","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"key":"R20-20260925","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"JCO"},{"key":"R21-20260925","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"key":"R22-20260925","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO-25-01733","article-title":"Genomics define malignant transformation in myeloma precursor conditions","volume":"44","author":"Maura","year":"2026","journal-title":"J Clin Oncol"},{"key":"R23-20260925","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO-25-00289","article-title":"Genomically smoldering multiple myeloma is not a distinct entity but a collection of monoclonal gammopathy of undetermined significance or multiple myeloma","volume":"44","author":"Aktas Samur","year":"2026","journal-title":"J Clin Oncol"},{"key":"R24-20260925","doi-asserted-by":"crossref","first-page":"e167629","DOI":"10.1172\/JCI167629","article-title":"Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy","volume":"133","author":"Robinson","year":"2023","journal-title":"J Clin Invest"},{"key":"R25-20260925","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"R26-20260925","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"suppl 1","key":"R27-20260925","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1182\/blood-2024-208837","article-title":"Single-cell RNA-sequencing of 6 million tumor and immune cells in 365 patients with MGUS and SMM demonstrates complex progressive changes in immune cell functionality with a distinct footprint on tumor cell biology and disease control","volume":"144","author":"Sklavenitis-Pistofidis","year":"2024","journal-title":"Blood"},{"key":"R28-20260925","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"European J Haematol"},{"key":"R29-20260925","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"key":"R30-20260925","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"key":"R31-20260925","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"R32-20260925","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"JCO"},{"key":"R33-20260925","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41467-024-55308-5","article-title":"Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial","volume":"16","author":"Nadeem","year":"2025","journal-title":"Nat Commun"},{"key":"R34-20260925","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Cancer Cell"},{"key":"R35-20260925","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R36-20260925","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2024-209809","article-title":"Results of the phase II randomized trial EMN15\/HOVON147: carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in patients with high-risk smoldering multiple myeloma","volume":"144","author":"Broijl","year":"2024","journal-title":"Blood"},{"key":"R37-20260925","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S2152-2650(21)02264-3","article-title":"P-137: ITHACA, a randomized multicenter phase 3 study of isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma: safety run-in preliminary results","volume":"21","author":"Ghobrial","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R38-20260925","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"R39-20260925","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"R40-20260925","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.23.02771","article-title":"Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance","volume":"42","author":"Mateos","year":"2024","journal-title":"JCO"},{"issue":"suppl 1","key":"R41-20260925","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2025-371","article-title":"Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)-autologous stem cell transplantation (ASCT)-krd-rd","volume":"146","author":"Mateos","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"R42-20260925","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2023-181811","article-title":"Fixed duration combination therapy with carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance leads to high rates of sustained MRD negativity in patients with high-risk smoldering multiple myeloma: long term follow up of an investigator initiated phase 2 trial","volume":"142","author":"Hill","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"R43-20260925","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2022-168930","article-title":"Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple myeloma\u2014results of the ASCENT trial","volume":"140","author":"Kumar","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"R44-20260925","doi-asserted-by":"crossref","first-page":"8040","DOI":"10.1200\/JCO.2022.40.16_suppl.8040","article-title":"B-PRISM (Precision Intervention Smoldering Myeloma): a phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"40","author":"Nadeem","year":"2022","journal-title":"JCO"},{"key":"R45-20260925","doi-asserted-by":"crossref","first-page":"e473316","DOI":"10.1200\/EDBK-25-473316","article-title":"Current and future directions of immunotherapies in multiple myeloma","volume":"45","author":"Biltibo","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"suppl 1","key":"R46-20260925","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood"},{"key":"R47-20260925","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1016\/S2152-2650(25)04011-X","article-title":"Safety and efficacy of linvoseltamab (LINVO) in patients (Pts) with high-risk smoldering multiple myeloma (HR-SMM): first results from the phase 2 LINKER-SMM1 trial","volume":"25","author":"Rodr\u00edguez-Otero","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R48-20260925","article-title":"Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial","author":"Nadeem","year":"2026","journal-title":"Nat Med"},{"key":"R49-20260925","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/hematology.2021000304","article-title":"Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies","volume":"2021","author":"Visram","year":"2021","journal-title":"Hematology"},{"key":"R50-20260925","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-024-00980-5","article-title":"Mode of progression in smoldering multiple myeloma: a study of 406 patients","volume":"14","author":"Abdallah","year":"2024","journal-title":"Blood Cancer J"},{"key":"R51-20260925","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41408-024-01159-8","article-title":"Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma","volume":"14","author":"Werly","year":"2024","journal-title":"Blood Cancer J"},{"key":"R52-20260925","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1182\/bloodadvances.2025016083","article-title":"Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring","volume":"9","author":"Kastritis","year":"2025","journal-title":"Blood Adv"},{"key":"R53-20260925","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-025-01312-x","article-title":"Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies","volume":"15","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Blood Cancer J"},{"key":"R54-20260925","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"R55-20260925","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2024-202676","article-title":"Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma","volume":"144","author":"Nadeem","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"R56-20260925","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2023-186397","article-title":"The early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: results of the ISTOPMM study","volume":"142","author":"R\u00f6gnvaldsson","year":"2023","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:02Z","timestamp":1790366462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000848","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}